Ethylphenidate

coronary artery disease, cardiomyopathy, structural cardiac abnormalities

EPH produces dose-dependent increases in heart rate, blood pressure, and body temperature through catecholamine reuptake inhibition. Pre-existing cardiovascular disease — including coronary artery disease, cardiomyopathy, and structural cardiac abnormalities — increases the risk of acute cardiac events.

EPH elevates blood pressure via norepinephrine reuptake inhibition. In individuals with uncontrolled hypertension, the additive pressor effect increases the risk of hypertensive crisis, stroke, and end-organ damage.

Abnormal heartbeat is reported by EPH users at community consensus level. Individuals with a history of arrhythmia face elevated risk of life-threatening cardiac rhythm disturbances under sympathomimetic stimulation.

MDMA releases serotonin, dopamine, and norepinephrine while EPH blocks DAT/NET reuptake. Combined use produces additive cardiovascular strain and elevated body temperature with potential for hyperthermia. No published EPH-MDMA-specific case data exists.

Active seizure disorders or use of medications that lower seizure threshold represent a relative contraindication. The risk is elevated in polydrug contexts where multiple seizure-threshold-lowering substances are combined.

Uncontrolled thyroid disease, particularly hyperthyroidism, increases sensitivity to sympathomimetic stimulation. EPH's catecholamine reuptake inhibition may produce exaggerated cardiovascular responses in these individuals.

No animal or human reproductive toxicity studies have been conducted for EPH. By structural analogy with methylphenidate — which carries documented pregnancy risk — EPH is contraindicated during pregnancy and lactation.

Co-administration of EPH with monoamine oxidase inhibitors creates risk of hypertensive crisis through dual impairment of catecholamine clearance (blocked reuptake + blocked enzymatic degradation). This contraindication is absolute by class analogy with all stimulant reuptake inhibitors.

Tramadol possesses mu-opioid agonism, mild serotonin reuptake inhibition, and norepinephrine reuptake inhibition. Both EPH and tramadol independently lower the seizure threshold, creating additive seizure risk. No published EPH-tramadol-specific fatality or interaction study exists; the lethal rating is precautionary.